These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 28193)

  • 1. Pamatolol: phase I evaluation of the pharmacodynamics of a cardioselective beta adrenoceptor blocking drug.
    Carruthers SG; Hosler JP; Pentikainen P; Azarnoff DL
    Clin Pharmacol Ther; 1978 Aug; 24(2):168-74. PubMed ID: 28193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The assessment in man of the beta-adrenoceptor blocking activity and cardioselectivity of H-I 42 BS, a long acting beta-adrenoceptor blocking drug.
    Pringle TH; Deering AH; Scott MG; Harron DW; Shanks RG
    Br J Clin Pharmacol; 1987 Apr; 23(4):411-23. PubMed ID: 2883988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker.
    Carruthers SG; Pentikainen P; Hosler JP; Azarnoff DL
    Clin Pharmacol Ther; 1979 Dec; 26(6):682-5. PubMed ID: 40725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic studies in man of the beta-adrenoceptor antagonist DL 071 IT.
    Radice M; Amanzio R; Criscuolo D
    Eur J Clin Pharmacol; 1979 Sep; 16(2):87-90. PubMed ID: 40801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic parameters of bevantolol in volunteers.
    Vermeij P; van Brummelen P
    Eur J Clin Pharmacol; 1986; 30(3):375-7. PubMed ID: 2874033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The assessment of the beta-adrenoceptor blocking activity and cardioselectivity of Koe 3290 in normal subjects.
    Pringle TH; McNeill AJ; Riddell JG; Shanks RG
    Br J Clin Pharmacol; 1987 Nov; 24(5):581-9. PubMed ID: 2893635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of atenolol, metroprolol, and pamatolol on cardiac and vascular beta-adrenoceptors in the rat.
    Johansson B
    J Cardiovasc Pharmacol; 1979; 1(3):287-98. PubMed ID: 94397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-blocking drug metipranolol: plasma levels and pharmacodynamic action in man.
    Mayer O; Cepelák V; Vitous J; Potmĕsil J
    Int J Clin Pharmacol Ther Toxicol; 1980 Mar; 18(3):113-9. PubMed ID: 6103879
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular beta-adrenergic blocking effects of bornaprolol in humans: relation to dose and plasma concentration.
    Cheymol G; Jaillon P; Lecoq B; Lecoq V; Cheymol A; Krumenacker M
    J Cardiovasc Pharmacol; 1987 Jun; 9(6):694-8. PubMed ID: 2442536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species differences in the metabolism of pamatolol, a cardioselective beta--adrenoceptor antagonist.
    Hoffmann KJ; Skånberg I; Borg KO
    Eur J Drug Metab Pharmacokinet; 1979; 4(3):163-73. PubMed ID: 43252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of the activity of beta-adrenoceptor antagonists in man.
    Taylor SH; Thadani U; Davidson C; singleton W; Myint S
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):305-6. PubMed ID: 240783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential haemodynamic effects induced by beta 1-(bisoprolol) or beta 2-(ICI 118,551) adrenoceptor blockade in man.
    Daul A; Johnston T; Reher M; Krüger M; Brodde OE
    J Hypertens Suppl; 1986 Dec; 4(6):S99-102. PubMed ID: 2886573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of betaxolol on heart rate at rest and during exercise.
    Kesteloot H; Missotten A; Coupez-Lopinot R; Sluyts R
    Acta Cardiol; 1982; 37(2):117-27. PubMed ID: 6125074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ro 31-1118, a new cardioselective beta-adrenoceptor antagonist. Pharmacokinetics and effects on heart rate and blood pressure in mild hypertensives.
    Jamieson M; Petrie JC; Webster J; Miller A; Harris RI; Francis RJ
    Eur J Clin Pharmacol; 1985; 29(4):395-9. PubMed ID: 2868899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug.
    Conway FJ; Fitzgerald JD; McAinsh J; Rowlands DJ; Simpson WT
    Br J Clin Pharmacol; 1976 Apr; 3(2):267-72. PubMed ID: 973955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of beta-blockers on exercise double product (systolic blood pressure x heart rate).
    Vukovich RA; Foley JE; Brown B; Willard DA; Buckley M; O'Kelly D; Fitzgerald D; Tormey W; Darragh A
    Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):167S-172S. PubMed ID: 37871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of the new beta-adrenoceptor blocking agent betaxolol (SL 75212) in man after repeated oral administration.
    Bianchetti G; Blatrix C; Gomeni R; Kilborn JR; Larribaud J; Lücker PW; Thebault JJ; Trocherie S; Morselli PL
    Arzneimittelforschung; 1980; 30(11):1912-6. PubMed ID: 6109538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol.
    Jennings G; Bobik A; Oddie C; Restall R
    Clin Pharmacol Ther; 1984 May; 35(5):594-603. PubMed ID: 6143634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ICI 118551 on bronchial beta-adrenoceptor function and exercise heart rate in normal man.
    Tattersfield AE; Cragg DJ
    Br J Clin Pharmacol; 1983 Dec; 16(6):587-90. PubMed ID: 6140938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral befunolol on heart rate and systolic blood pressure during submaximal exercise in man.
    Miki N; Furusho Y; Itaya K; Midorikawa K; Kumagai E; Terasawa M; Ihara S; Matoba T; Toshima H
    Jpn Circ J; 1980 Oct; 44(10):783-93. PubMed ID: 6107392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.